
|Videos|March 31, 2016
Dr. Sagar Lonial on Treating Patients With Smoldering Multiple Myeloma
Author(s)Sagar Lonial, MD
Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses whether or not to treat patients with smoldering multiple myeloma (SMM), or asymptomatic myeloma.
Advertisement
Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses whether or not to treat patients with smoldering multiple myeloma (SMM), or asymptomatic myeloma. Lonial suggests that rather than treat SMM, oncologists should move SMM patients who may need earlier treatment into the myeloma category.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
3
First Patients Dosed With TLX597-Tx in Trial for mHSPC
4
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
5































